[Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. Results of a multicenter long-term study].

Abstract

In an open multicenter trial, 90 patients with rheumatoid arthritis were treated with a daily dose of 6 mg auranofin. The duration of the treatment was 12 months. A significant improvement in the following parameters was observed: grip strength, number of swollen and painful joints after the 4th month, blood erythrocyte sedimentation rate decreased significantly after the 2nd month. Of the 90 patients, 56 (62.3%) completed the therapy, in 14 (15.5%) it was discontinued because of side effects and in 8 (8.9%) because of inefficacy. 12 patients (13.3%) stated other reasons for discontinuing the therapy (non compliance). The reported side-effects were mostly gastrointestinal, especially diarrhoea and loose stools. The evaluation of results referring to the duration of the disease shows that patients with a duration of less than 2 years reacted better to the improvement with auranofin therapy than patients with a longer sickness history.

• Authors: G Klein, H Schwann, B Mirtl, N Thumb, F Mayerhofer, F Singer, G Tausch, K Gaismayer, H Rieder, A Hartweger
• Journal: Zeitschrift fur Rheumatologie (Z Rheumatol) 1988 Sep-Oct Vol. 47 Issue 5 Pg. 342-6 ISSN: 0340-1855 [Print] Germany
• Vernacular Title: Klinische Wirksamkeit und Verträglichkeit von Auranofin bei Patienten mit chronischer Polyarthritis. Ergebnisse einer multizentrischen Langzeitstudie.
• PMID: 3149087 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Auranofin

Topics

• Adult
• Arthritis, Rheumatoid (drug therapy)
• Auranofin (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Drug Therapy, Combination
• Female
• Humans
• Long-Term Care
• Male
• Middle Aged